4 posts tagged with "drug-targets"

Overview​

Genetic studies have been very biased towards populations of European ancestry in western Europe and the United States of America, and this has led to a significant bias in the application of Mendelian randomization (MR) to identify intervention targets. In this project we worked with a leading international genetics consortium, the Global Biobank Meta-analysis Initiative (GBMI) to evaluate the differences in predicted drug target effects between African and European ancestry populations.

“The National Institute for Health and Care Research Bristol Biomedical Research Centre (NIHR Bristol BRC) has been awarded nearly £12 million of new funding for the next five years. The funding has been awarded to University Hospitals Bristol and Weston NHS Foundation Trust by the NIHR, with the University of Bristol a major partner.” - Press release

Overview​

This short animation explains how we use Mendelian randomization and colocalization to help prioritise drug targets. One of our aims in both  programme 4 of the MRC IEU and the Integrative Cancer Epidemiology Programme is to integrate such prioritizations with other data to help inform drug development.

Overview​